No

Vaccine

Routine immunization of children 2 months to 5 years of age against invasive disease caused by H. influenzae

Haemophilus b conjugate vaccines are not indicated for prevention of bronchitis or other infections due to H. influenzae in adults; adults with specific dysfunction or certain complement deficiencies who are at especially high risk of H. influenzae type b infection (HIV-infected adults); patients with Hodgkin's disease (vaccinated at least 2 weeks before the initiation of chemotherapy or 3 months after the end of chemotherapy)

C

Children with any febrile illness or active infection, known hypersensitivity to Haemophilus b polysaccharide vaccine (thimerosal), children who are immunosuppressed or receiving immunosuppressive therapy

Have epinephrine 1:1000 available; children in whom DTP or DT vaccination is deferred: The carrier proteins used in HbOC (but not PRP-OMP) are chemically and immunologically related to toxoids contained in DTP vaccine. Earlier or simultaneous vaccination with diphtheria or tetanus toxoids may be required to elicit an optimal anti-PRP antibody response to HbOC. In contrast, the immunogenicity of PRP-OMP is not affected by vaccination with DTP. In infants in whom DTP or DT vaccination is deferred, PRP-OMP may be advantageous for Haemophilus influenzae type b vaccination.

When administered during the same visit that DTP vaccine is given, the rates of systemic reactions do not differ from those observed only when DTP vaccine is administered. All serious adverse reactions must be reported to the U.S. Department of Health and Human Services (DHHS) Vaccine Adverse Event Reporting System (VAERS) 1-800-822-7967.

Cardiovascular: Edema

Dermatologic: Local erythema

Local: Increased risk of Haemophilus b infections in the week after vaccination

Miscellaneous: Warmth

>10%: Acute febrile reactions

1% to 10%:

Central nervous system: Fever (up to 102.2°F), irritability, lethargy

Gastrointestinal: Anorexia, diarrhea

Local: Irritation at injection site

<1%: Edema of the eyes/face, convulsions, fever (>102.2°F), unusual fatigue, urticaria, itching, vomiting, weakness, dyspnea

Decreased effect with immunosuppressive agents, immunoglobulins within 1 month may decrease antibody production

Keep in refrigerator, may be frozen (not diluent) without affecting potency; reconstituted Hib-Imune® remains stable for only 8 hours, whereas HibVAX® remain stable for 30 days when refrigerated

Stimulates production of anticapsular antibodies and provides active immunity to Haemophilus influenzae

The seroconversion following one dose of Hib vaccine for children 18 months or 24 months of age or older is 75% to 90% respectively

Onset of serum antibody responses: 1-2 weeks after vaccination

Duration: Immunity appears to last 1.5 years

Children: I.M.: 0.5 mL as a single dose should be administered according to one of the following "brand-specific" schedules; do not inject I.V.

It is not currently recommended that the various Haemophilus b conjugate vaccines be interchanged (ie, the same brand should be used throughout the entire vaccination series). If the health care provider does not know which vaccine was previously used, it is prudent that an infant, 2-6 months of age, be given a primary series of three doses.

HibTITER®:

Age at 1st dose: 2-6 months:

Primary series: 3 doses, 2 months apart; booster: 15 months (at least 2 months after previous dose)

Age at 1st dose: 7-11 months:

Primary series: 2 doses, 2 months apart; booster: 15 months (at least 2 months after previous dose)

Age at 1st dose: 12-14 months:

Primary series: 1 dose; booster: 15 months (at least 2 months after previous dose)

Age at 1st dose: 15-60 months:

Primary series: 1 dose; no booster

PedvaxHIB®:

Age at 1st dose: 2-6 months:

Primary series: 2 doses, 2 months apart; booster: 12 months (at least 2 months after previous dose)

Age at 1st dose: 7-11 months:

Primary series: 2 doses, 2 months apart; booster: 15 months (at least 2 months after previous dose)

Age at 1st dose: 12-14 months:

Primary series: 1 dose; booster: 15 months (at least 2 months after previous dose)

Age at 1st dose: 15-60 months:

Primary series: 1 dose; no booster

ProHIBiT®:

Age at 1st dose: 15-60 months:

Primary series: 1 dose; no booster

Give only I.M.

May interfere with interpretation of antigen detection tests

No information available to require special precautions

No effects or complications reported

May use acetaminophen for postdose fever

Defer immunization if infection or febrile illness present. Do not administer I.V.

Injection:

PedvaxHIB™: Purified capsular polysaccharide 15 mcg and Neisseria meningitidis OMPC 250 mcg per dose (0.5 mL)

ProHIBiT®: Purified capsular polysaccharide 25 mcg and conjugated diphtheria toxoid protein 18 mcg per dose (0.5 mL, 2.5 mL, 5 mL)

TriHIBit® vaccine [Tripedia® vaccine used to reconstitute ActHIB®]: 0.5 mL